Charles Gaulin, Associate Program Director of the Hematology and Medical Oncology Fellowship Program and Hematologic Oncologist at Dartmouth Hitchcock Medical Center, shared on LinkedIn:
“Congratulations to William Keegan for his presentation on DLBCL cell-of-origin classifier, COOrigin, this week at AMP 2026.
Traditional IHC-based algorithms have subjective limitations, and existing RNA classifiers can struggle with ambiguous cases. To address this, our team at Dartmouth Cancer Center developed an RNA-expression-based model trained on manually reviewed IHC labels.
COOrigin demonstrated 93.8% agreement with IHC/Hans in an 80-case cohort. It successfully classified a subset of cases considered indeterminate by gneSeqCOO.
Stop by Poster I063 to chat with our team!”
About AMP 2026
The AMP 2026 Annual Meeting & Expo, hosted by the Association for Molecular Pathology (AMP), is being held from November 10–14, 2026, in Seattle, Washington. The event brings together experts from across pathology, research, healthcare and the biotechnology industry to share the latest advances in molecular diagnostics and precision medicine.
The programme covers a wide range of topics, including cancer genomics, molecular testing, biomarkers, blood cancers, artificial intelligence and new diagnostic technologies. Attendees can take part in scientific presentations, educational sessions, poster discussions and networking activities.
For the oncology community, AMP 2026 offers an opportunity to present new research and discuss how developments in molecular testing and diagnostics can help improve cancer detection, better classify tumors and guide treatment decisions.
You may also be interested in: